{"nctId":"NCT00985166","briefTitle":"A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)","startDateStruct":{"date":"2000-08"},"conditions":["Measles","Mumps","Rubella","Varicella"],"count":801,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)","Biological: Comparator: Placebo"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: M-M-R II","Biological: Comparator: Placebo"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: M-M-R II","Biological: Comparator: Varivax"]}],"interventions":[{"name":"ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)","otherNames":["ProQuad"]},{"name":"Comparator: M-M-R II","otherNames":[]},{"name":"Comparator: Varivax","otherNames":[]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In good health\n* Received primary dose of M-M-R II at less than or equal to 12 months of age\n* Received primary dose of Varivax at less than or equal to 12 months of age\n* Negative history of varicella, zoster, measles, mumps, and rubella\n\nExclusion Criteria:\n\n* history of receiving more than once dose of M-M-R II or Varivax\n* Any immune impairment or deficiency\n* Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination\n* Vaccination with an inactive vaccine with in the past 14 days\n* Vaccination with a live vaccine within the past 30 days\n* Receipt of immune globulin, or blood product in the past 5 months","healthyVolunteers":true,"sex":"ALL","minimumAge":"4 Years","maximumAge":"6 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Antibody Response to Varicella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Varicella","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"322.2","spread":null},{"groupId":"OG001","value":"209.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Measles for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Measles","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1985.9","spread":null},{"groupId":"OG001","value":"2046.9","spread":null},{"groupId":"OG002","value":"2084.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Mumps for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Mumps","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"206.0","spread":null},{"groupId":"OG001","value":"308.5","spread":null},{"groupId":"OG002","value":"295.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Rubella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Rubella","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"217.3","spread":null},{"groupId":"OG001","value":"174.0","spread":null},{"groupId":"OG002","value":"154.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":397},"commonTop":["Injection site pain (ProQuad Injection-site)","Injection site pain (M-M-R II Injection-site)","Nasopharyngitis","Injection site erythema (ProQuad Injection-site)","Cough"]}}}